19:12:30 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Elos Medtech är verksamma inom medicinteknik. Bolaget arbetar med forskning och utveckling av produkter och medicintekniska komponenter för dentala- och ortopediska implantat. Verksamheten bedrivs via egna anläggningar runtom Norden, Nordamerika och Asien. Kunderna utgörs huvudsakligen av internationellt verksamma företagskunder. Huvudkontoret ligger i Göteborg.

Kalender

2024-02-22 Bokslutskommuniké 2023
2023-10-19 Kvartalsrapport 2023-Q3
2023-07-14 Kvartalsrapport 2023-Q2
2023-05-03 Årsstämma 2023
2023-04-26 Kvartalsrapport 2023-Q1
2023-02-23 Bokslutskommuniké 2022
2022-10-21 Kvartalsrapport 2022-Q3
2022-08-18 Kvartalsrapport 2022-Q2
2022-05-04 Ordinarie utdelning ELOS B 0.00 SEK
2022-05-03 Årsstämma 2022
2022-04-26 Kvartalsrapport 2022-Q1
2022-02-24 Bokslutskommuniké 2021
2021-12-22 Extra Bolagsstämma 2021
2021-10-20 Kvartalsrapport 2021-Q3
2021-07-16 Kvartalsrapport 2021-Q2
2021-05-04 Ordinarie utdelning ELOS B 1.50 SEK
2021-05-03 Årsstämma 2021
2021-04-28 Kvartalsrapport 2021-Q1
2021-02-24 Bokslutskommuniké 2020
2020-10-20 Kvartalsrapport 2020-Q3
2020-07-16 Kvartalsrapport 2020-Q2
2020-05-05 Kvartalsrapport 2020-Q1
2020-04-22 Ordinarie utdelning ELOS B 0.00 SEK
2020-04-21 Årsstämma 2020
2020-02-18 Bokslutskommuniké 2019
2019-10-24 Kvartalsrapport 2019-Q3
2019-07-18 Kvartalsrapport 2019-Q2
2019-04-24 Ordinarie utdelning ELOS B 1.00 SEK
2019-04-23 Kvartalsrapport 2019-Q1
2019-04-23 Årsstämma 2019
2019-02-18 Bokslutskommuniké 2018
2018-10-25 Kvartalsrapport 2018-Q3
2018-07-19 Kvartalsrapport 2018-Q2
2018-04-25 Ordinarie utdelning ELOS B 0.00 SEK
2018-04-24 Kvartalsrapport 2018-Q1
2018-04-24 Årsstämma 2018
2018-02-19 Bokslutskommuniké 2017
2017-10-24 Kvartalsrapport 2017-Q3
2017-08-25 Kvartalsrapport 2017-Q2
2017-04-27 Ordinarie utdelning ELOS B 1.30 SEK
2017-04-26 Årsstämma 2017
2017-04-26 Kvartalsrapport 2017-Q1
2017-02-24 Bokslutskommuniké 2016
2016-10-26 Kvartalsrapport 2016-Q3
2016-08-24 Kvartalsrapport 2016-Q2
2016-04-27 Ordinarie utdelning ELOS B 1.00 SEK
2016-04-26 Kvartalsrapport 2016-Q1
2016-04-26 Årsstämma 2016
2016-02-25 Bokslutskommuniké 2015
2015-10-23 Kvartalsrapport 2015-Q3
2015-08-21 Kvartalsrapport 2015-Q2
2015-04-28 Ordinarie utdelning ELOS B 2.00 SEK
2015-04-28 Bonusutdelning ELOS B 1
2015-04-27 Kvartalsrapport 2015-Q1
2015-04-27 Årsstämma 2015
2015-02-19 Bokslutskommuniké 2014
2014-10-24 Kvartalsrapport 2014-Q3
2014-08-22 Kvartalsrapport 2014-Q2
2014-04-30 Ordinarie utdelning ELOS B 2.00 SEK
2014-04-29 Kvartalsrapport 2014-Q1
2014-04-29 Årsstämma 2014
2014-02-21 Bokslutskommuniké 2013
2013-10-23 Kvartalsrapport 2013-Q3
2013-08-21 Kvartalsrapport 2013-Q2
2013-04-26 Ordinarie utdelning ELOS B 1.00 SEK
2013-04-25 Årsstämma 2013
2013-04-25 Kvartalsrapport 2013-Q1
2013-02-22 Bokslutskommuniké 2012
2012-10-26 Kvartalsrapport 2012-Q3
2012-08-22 Kvartalsrapport 2012-Q2
2012-04-24 Ordinarie utdelning ELOS B 1.50 SEK
2012-04-23 Årsstämma 2012
2012-04-23 Kvartalsrapport 2012-Q1
2012-02-24 Bokslutskommuniké 2011
2011-10-26 Kvartalsrapport 2011-Q3
2011-08-18 Kvartalsrapport 2011-Q2
2011-05-04 Ordinarie utdelning ELOS B 1.50 SEK
2011-05-03 Årsstämma 2011
2011-05-03 Kvartalsrapport 2011-Q1
2011-02-25 Bokslutskommuniké 2010
2010-10-27 Kvartalsrapport 2010-Q3
2010-08-19 Kvartalsrapport 2010-Q2
2010-04-29 Ordinarie utdelning ELOS B 0.00 SEK
2010-04-28 Kvartalsrapport 2010-Q1
2010-02-25 Bokslutskommuniké 2009
2009-10-23 Kvartalsrapport 2009-Q3
2009-08-20 Kvartalsrapport 2009-Q2
2009-04-30 Ordinarie utdelning ELOS B 1.50 SEK
2009-04-29 Årsstämma 1
2009-04-29 Kvartalsrapport 2009-Q1
2008-04-29 Ordinarie utdelning ELOS B 1.50 SEK
2007-04-26 Ordinarie utdelning ELOS B 0.50 SEK
2006-04-28 Ordinarie utdelning ELOS B 1.25 SEK
2005-05-20 Split ELOS B 1:2
2005-05-04 Ordinarie utdelning ELOS B 2.50 SEK
2004-04-30 Ordinarie utdelning ELOS B 0.00 SEK
2003-05-07 Ordinarie utdelning ELOS B 0.00 SEK
2002-04-26 Ordinarie utdelning ELOS B 0.00 SEK
2001-04-27 Ordinarie utdelning ELOS B 2.25 SEK
1995-06-15 Split ELOS B 1:2
2021-04-28 08:00:00

 A POSITIVE START TO THE YEAR

January - March 2021
  • Net sales for the first quarter amounted to SEK 171.2 (158.9) million, an increase of 7.7 percent compared to the same quarter last year. Net sales in local currencies increased by 14.2 percent.
  • Operating profit increased to SEK 25.0 (11.9) million, corresponding to an operating margin of 14.6 (7.5) percent.
  • Profit after net financial items increased to SEK 27.1 (6.6) million. Exchange rate differences and revaluation of interest rate swaps had a positive impact on net financial items of SEK 2.8 (2.2) million and SEK 2.1 (-4.3) million, respectively, resulting in a net financial gain of SEK 2.1 (-5.3) million.
  • Profit after tax amounted to SEK 20.0 (5.4) million.
  • Earnings per share amounted to SEK 2.48 (0.67).
  • Cash flow from operating activities was SEK 24.3 (9.0) million, amounting to SEK -11.5 (2.8) million after investments.

CEO JAN WAHLSTRÖM COMMENTS ON Q1

What a great start to the new year! We are once again a fully functioning business despite the ongoing pandemic. Net sales grew in the quarter and were up by 7.7 percent. In local currencies the growth was up by 14 percent.

In addition, earnings were also strong with an operating margin of 14.6 percent, which is a year-on-year increase of 110 percent. All business areas improved their profitability, partly thanks to a well balanced product mix and partly thanks to successful margin improvement measures.

The strongest growth was in Orthopedics, which grew 25 percent in the quarter. As predicted, our new robotic-assisted surgery businesses have given us a good foundation for 2021. Robotic surgery is a fast growing area and is on the agenda of all major orthopedic companies. This, and our results, show clearly that we have made the right strategic choice.

In Dental, net sales increased by nearly SEK 3 million on the previous quarter. The comparative period in 2020 was the best quarter in the company's history and this has an impact on year-on-year growth, which came in at -3 percent. Sales of our proprietary products are positive. Net sales of proprietary products grew 5.4 percent in the first quarter, despite a strong comparative period in 2020. Proprietary products still account for 14 percent of the Group's total net sales, which is above our long-term strategic goal for the second quarter in a row. Sales are mainly driven by our digital product range, Elos Accurate®.

Life Science reported growth of 6 percent. Here our focus has been on our new diagnostics business that we gained last fall and the new products that will go into production this year.

To ensure that we are able to grow with our partners, we are investing in our Skara site and in new machinery in Memphis. The expansion of our Skara site is proceeding at a good pace and we expect to be able to keep the timetable and take the new premises into use in the summer. We realize, however, that the relocation of machinery will be a complex operation that may result in brief shutdowns of production. In Memphis, our first new machines are being installed and validated, and our focus in the near future will therefore be on increasing staff levels.

A challenge that we face now in April is that it still uncertain what course the pandemic will take. Vaccine availability and vaccination rates will probably be crucial in stopping the pandemic, but until then the situation remains hard to predict. We attach great importance to ensuring access to raw materials to avoid disruptions in production, as the pandemic has created certain logistical challenges in the global market.

We got a positive start in 2021 - an important year dominated by two major investments that will be launched in both Skara and Memphis. It is challenging from several perspectives, but I look forward to the future with confidence.